Altimmune, Inc. (ALT)
NasdaqGM · Price as of · Nasdaq Real Time Price
- Analysts9
- Implied upside+453.8%
- Target range$11.00 to $28.00
- EPS expected-$0.13
- A year ago-$0.27
- Estimate range-$0.14 to -$0.10
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | August 13, 2026 | View on EDGAR |
| 10-Q | August 12, 2026 | 10-Q |
| 8-K | August 12, 2026 | 8-K |
| 4 | August 3, 2026 | View on EDGAR |
| 4 | August 3, 2026 | View on EDGAR |
| 8-K | July 28, 2026 | 8-K |
| 8-K | June 16, 2026 | FORM 8-K |
| SCHEDULE 13G/A | May 15, 2026 | View on EDGAR |
Frequently asked questions
When does ALT report earnings?
Altimmune, Inc. (ALT) is scheduled to report quarterly results on November 5, 2026, before the open. The 6-analyst consensus is -$0.13 per share for the quarter ended June 30, 2026, against -$0.27 a year earlier. It has beaten the consensus EPS estimate in 3 of the last four quarters.
What do analysts expect for ALT?
9 analysts cover Altimmune, Inc. (ALT). The consensus rating is Strong buy. The average price target is $17.22, in a range of $11.00 to $28.00.
Are insiders buying or selling ALT?
We have no qualifying Form 4 insider purchases or sales on record for Altimmune, Inc. (ALT). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see ALT SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed August 13, 2026.